Εξαγορά βόμβα: TEVA - Allergan

Στην εξαγορά της μονάδας γενοσήμων της Allergan, έναντι 40,5 δισ. δολαρίων σε μετρητά και μετοχές, προχωρά η Teva Pharmaceutical Industries, σε μια συμφωνία που θα καταστήσει την ισραηλινή εταιρεία μια από τις μεγαλύτερες φαρμακοβιομηχανίες του κόσμου.

Συγκεκριμένα, η Teva θα καταβάλει 33,75 δισ. δολάρια σε μετρητά και 6,75 δισ. δολάρια σε μετοχές, που αντιστοιχούν σε ποσοστό 10% της ισραηλινής εταιρείας.

Η συμφωνία - η μεγαλύτερη στην επιχειρηματική ιστορία του Ισραήλ - οδήγησε την Teva στο να αποσύρει την εχθρική προσφορά ύψους 40 δισ. δολαρίων για την απόκτηση της ανταγωνίστριάς της, Mylan. Παράλληλα, το deal θα επιτρέψει στην Allergan, που έχει την έδρα της στο Δουβλίνο, να επικεντρωθεί σε επώνυμα σκευάσματα και να μειώσει το χρέος της.

Η Teva, που ήδη είναι η μεγαλύτερη φαρμακοβιομηχανία γενοσήμων στον κόσμο, αναζητούσε νέες πηγές εσόδων για να αντιμετωπίσει τον ανταγωνισμό προς το βασικό της σκεύασμα για την σκλήρυνση κατά πλάκας.

Η συμφωνία αναμένεται να ολοκληρωθεί το πρώτο τρίμηνο του 2016.

Δείτε αναλυτικά το δελτίου τύπου

 

JERUSALEM--(BUSINESS WIRE)--Jul. 27, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that it has signed a definitive agreement with Allergan plc (NYSE:AGN) to acquire Allergan Generics in a transaction valued at $40.5 billion. Upon closing, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion, representing an estimated under 10% ownership stake in Teva, with the number of Teva shares determined based on Teva’s volume weighted average trading prices during the 15 days prior to the announcement and five days following the announcement. Teva believes the acquisition will be significantly accretive to non-GAAP EPS, including expected double-digit non-GAAP EPS accretion in 2016 and more than 20% accretion in year two and year three following the close of the transaction. The transaction was unanimously approved by the Boards of Directors of Teva and Allergan and is expected to close in the first quarter of 2016.

How Apple’s ResearchKit Is Changing The Pharmaceutical Industry

When Apple announced, last year, that it was developing a watch that had the functions of a medical device, it became clear that the company was eyeing the $3 trillion health care industry; that the tech industry sees medicine as the next frontier for exponential growth.
Apple’s recent announcement of ResearchKit shows that it has an even greater ambition: It wants to also transform the pharmaceutical industry by changing the way clinical trials are done.
ResearchKit is a platform that will let app builders capture and upload data from patients who have a particular disease. Our smartphones already monitor our activity levels, lifestyles and habits. They know where we go, how fast we move, and when we sleep. Some smartphone apps already try to judge our emotions and health based on this information; to be sure, they can ask us questions.
ResearchKit apps will enable constant monitoring of symptoms and of reactions to medications. Today, clinical trials are done on a relatively small number of patients, and pharmaceutical companies sometimes choose to ignore information that does not suit them. Data that our devices gather will be used to accurately analyse what medications patients have taken, in order to determine which of them truly had a positive effect; which simply created adverse reactions and new ailments; and which did both.

Greece: More Than Next Week's Medicine Supply At Risk

 PharmExec

There are some evident challenges for pharma in the ongoing Greek crisis. But, writes Reflector, there are some less evident challenges which may, over time, prove to be more difficult for the industry to cope with.

First, the immediate challenges. And because the crisis is, at least in its origins, economic, the economic challenges are the most obvious. How to make money through normal commerce in a market which has become conspicuously abnormal? For years drug manufacturers have had difficulty in obtaining payment for their supplies, in the same way as wholesalers and hospitals have had difficulty in obtaining the money to pay manufacturers because of interruptions to their own revenue streams. Estimates of the level of unpaid debts vary, but European manufacturers have spoken of carrying unpaid invoices worth more than north of a million dollars. And whichever way the broader discussions with international creditors of a resolution to Greece’s problems play out over the summer, there is little prospect of things getting better, and every prospect of them getting worse. Those debts are likely to pile up.

The abnormality of the market has other facets. Exchange controls and sharpened economic decline have created new liquidity constraints that impede patients from paying pharmacists, pharmacists from paying wholesalers, and wholesalers paying manufacturers. Wholesalers promised the minister of health to continue to supply the market with the usual quantities as well as with the  usual economic terms – but with the obvious risk of cashflow problems. One wholesaler said: “I really do not know (and this is my greatest fear) whether the medicines which I supply to pharmacies will be paid in euro, drachmas or will never be paid if the economy collapses.”

Greek Crisis Prompts Industry Clash Over Drug Prices and Supplies

The Wall Street Journal | Ed Silverman

Despite the uncertainty facing the Greek economy, the leading pharmaceutical industry trade group in Europe maintains that shipments of medicines will continue. At the same time, the group is pressing the European Commission to take steps to ensure that prices and supplies are not disrupted if Greece introduces its own currency.

In response to questions, a spokesman for the European Federation of Pharmaceutical Industries and Associations says supplies are continuing and that “we have discussed no limit, at present.” Drug makers are owed about $1.2 billion by hospitals and other payers, he says, adding that talks about supplies are expected to be held this evening, given the fast-changing nature of the Greek economic crisis.